BioCryst Pharmaceuticals Inc. (BCRX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

BioCryst Pharmaceuticals ... (BCRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.24

-0.69 (-8.70%)

At close: Jan 14, 2025, 3:59 PM

7.35

1.59%

After-hours Jan 14, 2025, 06:05 PM EST

undefined% (undefined)

Bid	7.11
Market Cap	1.50B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.61
PE Ratio (ttm)	-11.86
Forward PE	n/a
Analyst	Buy

Ask	8.5
Volume	2,079,121
Avg. Volume (20D)	2,084,295
Open	7.97
Previous Close	7.93
Day's Range	7.24 - 8.02
52-Week Range	4.03 - 8.88
Beta	undefined

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 4, 1994

Employees 536

Stock Exchange NASDAQ

Ticker Symbol BCRX

Website https://www.biocryst.com

Analyst Forecast

According to 6 analyst ratings, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 65.86% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

BioCryst Pharmaceuticals Inc. is scheduled to release its earnings on Feb 24, 2025, before market opens.
Analysts project revenue of $127.72M, reflecting a 36.74% YoY growth and earnings per share of -0.06, making a -78.57% decrease YoY.

Why Price Moved

2 months ago · Source

-12.81%

BioCryst Pharma shares are trading lower following... Unlock content with Pro Subscription

5 months ago · Source

+6.98%

BioCryst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results. Additionally, the company raised its FY24 Orladeyo revenue guidance above estimates.

News

1 month ago · seekingalpha.com

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

BioCryst remains a "Buy" due to ORLADEYO's proven success, potential growth, and management's confidence despite significant competition and a one-dimensional revenue stream. Q3 2024 showed mixed resu...

2 months ago · seekingalpha.com

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie G...

2 months ago · zacks.com

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.

2 months ago · zacks.com

How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%

The consensus price target hints at a 79.5% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...